Montreal, Quebec – January 23, 2020 – Emovi, Inc., the manufacturer of KneeKGTM, today announces the release of a commissioned white paper titled “Knee Osteoarthritis in a Commercially Insured Population: A Claims-Based Analysis.” Emovi engaged with actuarial and highly reputable firm Milliman to examine the diagnostic and treatment patterns for patients with symptomatic osteoarthritis (OA) of the knee and contribution to healthcare insurance costs.
The report explores commercially insured knee OA patients’ treatment patterns, utilization of services and healthcare expenditures specific to knee OA and potential opportunities to improve the efficiency of managing this chronic condition.
“Knee osteoarthritis represents a complex musculoskeletal disorder with multiple risk factors, among which is the knee dynamic malalignment, which is known to be predictive of OA progression. In itself, Knee OA is a highly prevalent, disabling joint disease and becomes very costly as the population grows,” said Michelle Laflamme, CEO of Emovi. “The Milliman healthcare claims-based analysis provides real-world evidence specific to knee OA costs. The results highlight the cost burden of knee OA, and the potential opportunity for alternative, non-invasive treatment options for improving the efficiency of managing this chronic condition. We believe that the KneeKG could be part of that solution. The KneeKG brings a clinically validated solution to the healthcare system and knee OA patients by giving the right information about the knee dynamic malalignment and completely changing the treatment paradigm with much better outcomes.”
Key Knee OA healthcare cost statistics and findings from the Milliman report include:
- Knee OA patients contribute 5.6% of the total adult commercial study population spend
- Knee-related services among the knee OA population account for 1.7% of the total adult population spend
- Knee-related services contribute 31% of the average annual spend for the knee OA population; of the knee-related costs:
- 59.3% is associated with knee Arthroplasty (total, partial and revision)
- 12.1% is associated with arthroscopy and minor knee surgery
- 10.6% is associated with knee injections
- 4.9% is associated with MRIs
The full white paper can be accessed here: https://www.milliman.com/insight/Knee-Osteoarthritis-in-a-Commercially-Insured-Population
About Emovi Inc.
Headquartered in Montreal, Emovi is a medical device company that develops products for knee joint assessment to restore patient quality of life. In partnership with the Quebec university research community, including the CRCHUM, École de Technologie supérieure (ÉTS), and TELUQ. Emovi completed the development of the KneeKG, a unique clinical tool evaluating knee functional deficiencies linked to patients’ symptoms and pathology progression.
Emovi owns multiple patents and the exclusive worldwide license to commercialize KneeKG: https://emovi.ca
About Milliman, Inc.
Milliman is among the world’s largest providers of actuarial and related products and services. The firm has consulting practices in healthcare, property & casualty insurance, life insurance, and financial services, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe.
For further information, visit www.milliman.com.
Company Name: Emovi, Inc.
Contact Person: Patti D. Hill
Email: Send Email
Address:25 Mozart E. Ave Suite 305